# Matteo Benelli

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7768440/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 92 papers | 6,027 citations | 147726 31 h-index | 79644 73 g-index |
| 96 all docs | 96 docs citations | 96 times ranked | 10612 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305. | 15.2 | 1,193 |
| 2 | Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436. | 3.3 | 839 |
| 3 | SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer. Science, 2017, 355, 84-88. | 6.0 | 759 |
| 4 | N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 30, 563-577. | 7.7 | 394 |
| 5 | Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 2018, 9, 2404. | 5.8 | 246 |
| 6 | EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biology, 2013, 14, R120. | 13.9 | 213 |
| 7 | Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript. Bioinformatics, 2012, 28, 3232-3239. | 1.8 | 154 |
| 8 | Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Journal of Clinical Investigation, 2020, 130, 1653-1668. | 3.9 | 122 |
| 9 | Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Frontiers in Oncology, 2019, 9, 666. | 1.3 | 113 |
| 10 | H Â3 ÂM Â2 : detection of runs of homozygosity from whole-exome sequencing data. Bioinformatics, 2014, 30, 2852-2859. | 1.8 | 88 |
| 11 | Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2017, 128, 341-358. | 3.9 | 83 |
| 12 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811. | 7.7 | 79 |
| 13 | Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. Npj Breast Cancer, 2018, 4, 38. | 2.3 | 78 |
| 14 | Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549. | 5.8 | 76 |
| 15 | Novel Î±-Actinin 2 Variant Associated With Familial Hypertrophic Cardiomyopathy and Juvenile Atrial Arrhythmias. Circulation: Cardiovascular Genetics, 2014, 7, 741-750. | 5.1 | 74 |
| 16 | Genome-wide plasma DNA methylation features of metastatic prostate cancer. Journal of Clinical Investigation, 2020, 130, 1991-2000. | 3.9 | 68 |
| 17 | Read count approach for DNA copy number variants detection. Bioinformatics, 2012, 28, 470-478. | 1.8 | 67 |
| 18 | Bioinformatics for Next Generation Sequencing Data. Genes, 2010, 1, 294-307. | 1.0 | 65 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Detecting common copy number variants in high-throughput sequencing data by using JointSLM algorithm. Nucleic Acids Research, 2011, 39, e65-e65. | 6.5 | 63 |
| 20 | Clinical Significance of Rare Copy Number Variations in Epilepsy. Archives of Neurology, 2012, 69, 322. | 4.9 | 61 |
| 21 | CEBPA â€“double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. Haematologica, 2017, 102, 529-540. | 1.7 | 61 |
| 22 | Expanding the mutational spectrum of LZTR1 in schwannomatosis. European Journal of Human Genetics, 2015, 23, 963-968. | 1.4 | 58 |
| 23 | A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK/PI3K induced malignant growth. DMM Disease Models and Mechanisms, 2017, 10, 15-28. | 1.2 | 58 |
| 24 | Sequencing of a â€˜mouse azoospermiaâ€™ gene panel in azoospermic men: identification of RNF212 and STAG3 mutations as novel genetic causes of meiotic arrest. Human Reproduction, 2019, 34, 978-988. | 0.4 | 58 |
| 25 | 372Âkb microdeletion in 18q12.3 causing SETBP1 haploinsufficiency associated with mild mental retardation and expressive speech impairment. European Journal of Medical Genetics, 2012, 55, 216-221. | 0.7 | 55 |
| 26 | Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care, 2017, 12, 304-308. | 0.8 | 53 |
| 27 | Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4870-4882. | 3.2 | 49 |
| 28 | Contemporary genetic testing in inherited cardiac disease. Journal of Cardiovascular Medicine, 2018, 19, 1-11. | 0.6 | 48 |
| 29 | LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. Nature Communications, 2019, 10, 307. | 5.8 | 44 |
| 30 | Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 3574. | 1.7 | 42 |
| 31 | Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. Clinical Cancer Research, 2020, 26, 2131-2139. | 3.2 | 40 |
| 32 | Tumor purity quantification by clonal DNA methylation signatures. Bioinformatics, 2018, 34, 1642-1649. | 1.8 | 36 |
| 33 | Cell-Free DNA-Methylation-Based Methods and Applications in Oncology. Biomolecules, 2020, 10, 1677. | 1.8 | 31 |
| 34 | Dependence of apparent diffusion coefficient measurement on diffusion gradient direction and spatial position â€“ A quality assurance intercomparison study of forty-four scanners for quantitative diffusion-weighted imaging. Physica Medica, 2018, 55, 135-141. | 0.4 | 30 |
| 35 | Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptorâ€“positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus | 1.3 | 30 |
| 36 | Persistence of odd-even staggering in charged-fragment yields from <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:msup><mml:mrow /><mml:mn>112</mml:mn></mml:msup></mml:math>Sn<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:math><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:msup><mml:mrow /><mml:mml: | 1.1 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | EX-HOM (EXome HOMozygosity): A Proof of Principle. Human Heredity, 2011, 72, 45-53. | 0.4 | 27 |
| 38 | A shifting level model algorithm that identifies aberrations in array-CGH data. Biostatistics, 2010, 11, 265-280. | 0.9 | 26 |
| 39 | CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treatment Reviews, 2021, 93, 102136. | 3.4 | 25 |
| 40 | Sphingosine 1-Phosphate Induces Differentiation of Mesoangioblasts towards Smooth Muscle. A Role for GATA6. PLoS ONE, 2011, 6, e20389. | 1.1 | 23 |
| 41 | Hypovitaminosis D and osteopenia/osteoporosis in a haemophilia population: a study in <scp>HCV</scp>/<scp>HIV</scp> or <scp>HCV</scp> infected patients. Haemophilia, 2013, 19, 126-133. | 1.0 | 23 |
| 42 | Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib+. Cells, 2020, 9, 668. | 1.8 | 23 |
| 43 | ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data. BMC Genomics, 2018, 19, 960. | 1.2 | 22 |
| 44 | A novel founder MYO15A frameshift duplication is the major cause of genetic hearing loss in Oman. Journal of Human Genetics, 2017, 62, 259-264. | 1.1 | 21 |
| 45 | Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Research, 2019, 21, 71. | 2.2 | 19 |
| 46 | A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. Breast Cancer Research and Treatment, 2018, 170, 329-341. | 1.1 | 17 |
| 47 | Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. Cancer Treatment Reviews, 2020, 82, 101935. | 3.4 | 17 |
| 48 | Tumor Necrosis Factor Î± Influences Phenotypic Plasticity and Promotes Epigenetic Changes in Human Basal Forebrain Cholinergic Neuroblasts. International Journal of Molecular Sciences, 2020, 21, 6128. | 1.8 | 17 |
| 49 | A very fast and accurate method for calling aberrations in array-CGH data. Biostatistics, 2010, 11, 515-518. | 0.9 | 16 |
| 50 | A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene. PLoS ONE, 2015, 10, e0129099. | 1.1 | 16 |
| 51 | Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open, 2019, 4, e000489. | 2.0 | 14 |
| 52 | Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Research, 2021, 23, 38. | 2.2 | 14 |
| 53 | On the dependence of quantitative diffusion-weighted imaging on scanner system characteristics and acquisition parameters: A large multicenter and multiparametric phantom study with unsupervised clustering analysis. Physica Medica, 2021, 85, 98-106. | 0.4 | 14 |
| 54 | Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer. Cell Systems, 2022, 13, 183-193.e7. | 2.9 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Whole exome sequencing (WES) of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer (NEPC) informs tumor heterogeneity.. Journal of Clinical Oncology, 2017, 35, 5011-5011. | 0.8 | 12 |
| 56 | 16p11.2 de novo microdeletion encompassing SRCAP gene in a patient with speech impairment, global developmental delay and behavioural problems. European Journal of Medical Genetics, 2014, 57, 649-653. | 0.7 | 10 |
| 57 | Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. Oncotarget, 2016, 7, 30365-30378. | 0.8 | 10 |
| 58 | PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer. Npj Breast Cancer, 2022, 8, 24. | 2.3 | 9 |
| 59 | Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. Cancers, 2021, 13, 2640. | 1.7 | 8 |
| 60 | Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 2022, 164, 39-51. | 1.3 | 8 |
| 61 | A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. Cytometry Part B - Clinical Cytometry, 2013, 84B, 71-81. | 0.7 | 7 |
| 62 | Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. European Urology Oncology, 2019, 2, 277-285. | 2.6 | 7 |
| 63 | Comprehensive Analysis of Radiomic Datasets by RadAR. Cancer Research, 2020, 80, 3170-3174. | 0.4 | 7 |
| 64 | The incremental value of computed tomography of COVID-19 pneumonia in predicting ICU admission. Scientific Reports, 2021, 11, 15619. | 1.6 | 7 |
| 65 | Charting differentially methylated regions in cancer with Rocker-meth. Communications Biology, 2021, 4, 1249. | 2.0 | 7 |
| 66 | Validation of a method for noninvasive prenatal testing for fetal aneuploidies risk and considerations for its introduction in the Public Health System. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 710-716. | 0.7 | 6 |
| 67 | WNP: A Novel Algorithm for Gene Products Annotation from Weighted Functional Networks. PLoS ONE, 2012, 7, e38767. | 1.1 | 5 |
| 68 | Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia. Experimental Hematology, 2015, 43, 869-879.e22. | 0.2 | 4 |
| 69 | An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989160. | 1.4 | 3 |
| 70 | Exploring Serum NMR-Based Metabolomic Fingerprint of Colorectal Cancer Patients: Effects of Surgery and Possible Associations with Cancer Relapse. Applied Sciences (Switzerland), 2021, 11, 11120. | 1.3 | 3 |
| 71 | Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer. , 2020, , . | | 2 |
| 72 | Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. Breast, 2019, 48, S81-S84. | 0.9 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.. Journal of Clinical Oncology, 2018, 36, 12031-12031. | 0.8 | 1 |
| 74 | Moment estimation in discrete shifting level model applied to fast arrayâ€CGH segmentation. Statistica Neerlandica, 2013, 67, 227-262. | 0.9 | 0 |
| 75 | Exome sequencing in primary melanoma identifies novel drivers of melanoma progression. Journal of Translational Medicine, 2015, 13, P2. | 1.8 | 0 |
| 76 | Abstract B39: Exome sequencing in primary melanoma identifies novel drivers of melanoma progression. , 2015, , . | | 0 |
| 77 | Abstract LB-122: Tumor heterogeneity in castration resistant neuroendocrine prostate cancer from whole exome sequencing of circulating tumor DNA. , 2017, , . | | 0 |
| 78 | Abstract LB-085: RB loss-induced genome wide E2F1 reprogramming drive advanced prostate cancer. , 2017, , . | | 0 |
| 79 | Abstract 4165:SOX2promotes lineage plasticity and antiandrogen resistance inTP53andRB1deficient prostate cancer. , 2017, , . | | 0 |
| 80 | A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. Journal of Clinical Oncology, 2018, 36, 570-570. | 0.8 | 0 |
| 81 | Abstract IA19: Phenotype plasticityâ€"a novel mechanism of targeted therapy resistance. , 2018, , . | | 0 |
| 82 | Abstract B040: Differential impact of RB status on E2F1 reprogramming in human cancer. , 2018, , . | | 0 |
| 83 | Abstract IA03: Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer. , 2018, , . | | 0 |
| 84 | Abstract A078: Towards understanding noncanonical phosphatidylinositol kinases in the maintenance of prostate metabolism. , 2018, , . | | 0 |
| 85 | Abstract A042: Modulation of translation regulation by N6-methyladenosine in prostate cancer. , 2018, , . | | 0 |
| 86 | Abstract 2471: Pan-cancer catalog of Differentially Methylated Regions by Rocker-meth, a new computational method. , 2019, , . | | 0 |
| 87 | Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial. , 2019, , . | | 0 |
| 88 | Abstract P4-04-07: A DNA-methylation signature to predict resistance to the CDK4/6 inhibitor palbociclib. , 2020, , . | | 0 |
| 89 | Abstract 2488: Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program. , 2020, , . | | 0 |
| 90 | Abstract P5-06-11: Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC). , 2020, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Abstract P5-13-13: PIK3CA mutations co-occurring with copy number gain identify patients with adverse outcome and potentially different treatment sensitivity among hormone receptor positive and HER2 negative metastatic breast cancer. Cancer Research, 2022, 82, P5-13-13-P5-13-13. | 0.4 | 0 |
| 92 | Abstract 3012: Single-cell transcriptomic characterization of luminal breast cancer cell lines with acquired resistance to the CDK4/6 inhibitor palbociclib. , 2019, , . | | 0 |